305 related articles for article (PubMed ID: 31040267)
21. CST6 protein and peptides inhibit breast cancer bone metastasis by suppressing CTSB activity and osteoclastogenesis.
Li X; Liang Y; Lian C; Peng F; Xiao Y; He Y; Ma C; Wang Y; Zhang P; Deng Y; Su Y; Luo C; Kong X; Yang Q; Liu T; Hu G
Theranostics; 2021; 11(20):9821-9832. PubMed ID: 34815788
[No Abstract] [Full Text] [Related]
22. A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment.
Kang J; Choi YJ; Seo BY; Jo U; Park SI; Kim YH; Park KH
Sci Rep; 2019 Jun; 9(1):8726. PubMed ID: 31217507
[TBL] [Abstract][Full Text] [Related]
23. IL-6 Enhances Osteocyte-Mediated Osteoclastogenesis by Promoting JAK2 and RANKL Activity In Vitro.
Wu Q; Zhou X; Huang D; Ji Y; Kang F
Cell Physiol Biochem; 2017; 41(4):1360-1369. PubMed ID: 28278513
[TBL] [Abstract][Full Text] [Related]
24. Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells.
Nakata A; Tsujimura T; Sugihara A; Okamura H; Iwasaki T; Shinkai K; Iwata N; Kakishita E; Akedo H; Terada N
Anticancer Res; 1999; 19(5B):4131-8. PubMed ID: 10628364
[TBL] [Abstract][Full Text] [Related]
25. Circular RNA circIKBKB promotes breast cancer bone metastasis through sustaining NF-κB/bone remodeling factors signaling.
Xu Y; Zhang S; Liao X; Li M; Chen S; Li X; Wu X; Yang M; Tang M; Hu Y; Li Z; Yu R; Huang M; Song L; Li J
Mol Cancer; 2021 Jul; 20(1):98. PubMed ID: 34325714
[TBL] [Abstract][Full Text] [Related]
26. Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways.
Zheng Y; Chow SO; Boernert K; Basel D; Mikuscheva A; Kim S; Fong-Yee C; Trivedi T; Buttgereit F; Sutherland RL; Dunstan CR; Zhou H; Seibel MJ
J Bone Miner Res; 2014 Sep; 29(9):1938-49. PubMed ID: 24676805
[TBL] [Abstract][Full Text] [Related]
27. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.
Strazic-Geljic I; Guberovic I; Didak B; Schmid-Antomarchi H; Schmid-Alliana A; Boukhechba F; Bouler JM; Scimeca JC; Verron E
Biochem Pharmacol; 2016 Sep; 116():11-21. PubMed ID: 27378505
[TBL] [Abstract][Full Text] [Related]
28. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
[TBL] [Abstract][Full Text] [Related]
29. Morusin inhibits breast cancer-induced osteolysis by decreasing phosphatidylinositol 3-kinase (PI3K)-mTOR signalling.
Zhang L; Li W; Chen X; Cao D; You S; Shi F; Luo Z; Li H; Zeng X; Song Y; Li N; Akimoto Y; Rui G; Chen Y; Wu Z; Xu R
Chem Biol Interact; 2024 May; 394():110968. PubMed ID: 38522564
[TBL] [Abstract][Full Text] [Related]
30. AG490 suppresses interleukin-34-mediated osteoclastogenesis in mice bone marrow macrophages.
Cheng X; Wan QL; Li ZB
Cell Biol Int; 2017 Jun; 41(6):659-668. PubMed ID: 28378938
[TBL] [Abstract][Full Text] [Related]
31. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
32. Oroxylin A suppresses breast cancer-induced osteoclastogenesis and osteolysis as a natural RON inhibitor.
Chen Y; Zheng J; Mo L; Chen F; Li R; Wang Y; Liang Q; Chen Z; Dai W; Chen L; Yan P; Zhou H; Li X
Phytomedicine; 2024 Jul; 129():155688. PubMed ID: 38728920
[TBL] [Abstract][Full Text] [Related]
33. Circulating interleukin-8 levels explain breast cancer osteolysis in mice and humans.
Kamalakar A; Bendre MS; Washam CL; Fowler TW; Carver A; Dilley JD; Bracey JW; Akel NS; Margulies AG; Skinner RA; Swain FL; Hogue WR; Montgomery CO; Lahiji P; Maher JJ; Leitzel KE; Ali SM; Lipton A; Nicholas RW; Gaddy D; Suva LJ
Bone; 2014 Apr; 61():176-85. PubMed ID: 24486955
[TBL] [Abstract][Full Text] [Related]
34. Artemisinin-Daumone Hybrid Inhibits Cancer Cell-Mediated Osteolysis by Targeting Cancer Cells and Osteoclasts.
Ma GT; Lee SK; Park KK; Park J; Son SH; Jung M; Chung WY
Cell Physiol Biochem; 2018; 49(4):1460-1475. PubMed ID: 30205376
[TBL] [Abstract][Full Text] [Related]
35. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
36. Muscadine grape skin extract can antagonize Snail-cathepsin L-mediated invasion, migration and osteoclastogenesis in prostate and breast cancer cells.
Burton LJ; Smith BA; Smith BN; Loyd Q; Nagappan P; McKeithen D; Wilder CL; Platt MO; Hudson T; Odero-Marah VA
Carcinogenesis; 2015 Sep; 36(9):1019-27. PubMed ID: 26069256
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
[TBL] [Abstract][Full Text] [Related]
38. The flavonoid p-hydroxycinnamic acid mediates anticancer effects on MDA-MB-231 human breast cancer cells in vitro: Implications for suppression of bone metastases.
Yamaguchi M; Murata T; Shoji M; Weitzmann MN
Int J Oncol; 2015 Oct; 47(4):1563-71. PubMed ID: 26238204
[TBL] [Abstract][Full Text] [Related]
39. A CTGF-RUNX2-RANKL Axis in Breast and Prostate Cancer Cells Promotes Tumor Progression in Bone.
Kim B; Kim H; Jung S; Moon A; Noh DY; Lee ZH; Kim HJ; Kim HH
J Bone Miner Res; 2020 Jan; 35(1):155-166. PubMed ID: 31505052
[TBL] [Abstract][Full Text] [Related]
40. Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer.
Zinonos I; Luo KW; Labrinidis A; Liapis V; Hay S; Panagopoulos V; Denichilo M; Ko CH; Yue GG; Lau CB; Ingman W; Ponomarev V; Atkins GJ; Findlay DM; Zannettino AC; Evdokiou A
Int J Oncol; 2014 Aug; 45(2):532-40. PubMed ID: 24865346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
